- SR One announced it has closed a second venture fund at $600 million.
SR One – a transatlantic life sciences investment firm – announced the closing of its second fund at over $600 million, which substantially exceeded the target of $500 million. And Fund II is the second fund since SR One spun out from GlaxoSmithKline in 2020 to form a fully independent investment firm. The investor base of existing and new limited partners includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds, and family offices.
Through Fund II, SR One will continue investing in biotechnology companies that have the potential to address significant gaps in the current treatment landscape. And SR One’s investment strategy focuses on providing financial and direct operational support to help its portfolio companies advance programs through value-generating inflection points.
KEY QUOTES:
“We received an incredible response to the fund and are grateful to our limited partners for their continued support and confidence in our team. SR One’s model is built upon active collaboration and our ability to roll up our sleeves and help build value through multiple inflection points. We seek to partner with entrepreneurs building elite biotechnology companies, and we look forward to the potential development of new medicines for patients that Fund II may help bring to the market.”
— Simeon George, MD, Co-Founder and Chief Executive Officer, SR One
“We have built a team of seasoned investors and venture partners who I believe are well-positioned to continue SR One’s history of productive investment. With Fund II, we hope to continue to apply our tried and tested partnership model in an effort to benefit the companies in which we invest and, ultimately, the patients and families that they serve.”
— Rajeev Dadoo, PhD, Managing Partner, SR One
